IDEAYA Biosciences, Inc. financial data

Symbol
IDYA on Nasdaq
Industry
Pharmaceutical Preparations
Location
5000 Shoreline Ct, Suite 300, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.16K % +42.4%
Debt-to-equity 4.25 % -40.3%
Return On Equity -19.4 % +20.3%
Return On Assets -18.6 % +18.2%
Operating Margin -5.73K % -1031%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 86.4M shares +34.1%
Common Stock, Shares, Outstanding 86.4M shares +47.3%
Entity Public Float 1.3B USD +164%
Common Stock, Value, Issued 9K USD +50%
Weighted Average Number of Shares Outstanding, Basic 86.2M shares +43.6%
Weighted Average Number of Shares Outstanding, Diluted 86.2M shares +43.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.92M USD -83.3%
Research and Development Expense 193M USD +67.4%
General and Administrative Expense 35.4M USD +31.2%
Operating Income (Loss) -225M USD -88.9%
Nonoperating Income (Expense) 46.6M USD +196%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -178M USD -72.6%
Earnings Per Share, Basic -2.32 USD/shares -17.2%
Earnings Per Share, Diluted -2.32 USD/shares -17.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 400M USD +164%
Marketable Securities, Current 520M USD +64%
Assets, Current 932M USD +93.3%
Property, Plant and Equipment, Net 8.24M USD +33%
Operating Lease, Right-of-Use Asset 18.4M USD +1265%
Other Assets, Noncurrent 75K USD -30.6%
Assets 1.24B USD +133%
Accounts Payable, Current 12.6M USD +143%
Employee-related Liabilities, Current 7.43M USD +19.2%
Accrued Liabilities, Current 28.1M USD +73.5%
Contract with Customer, Liability, Current 1.44M USD -86%
Liabilities, Current 40.7M USD +63.3%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 18.8M USD
Liabilities 59.5M USD +139%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.84M USD
Retained Earnings (Accumulated Deficit) -493M USD -56.7%
Stockholders' Equity Attributable to Parent 1.18B USD +132%
Liabilities and Equity 1.24B USD +133%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.8M USD -57.4%
Net Cash Provided by (Used in) Financing Activities 349M USD +11831%
Net Cash Provided by (Used in) Investing Activities -354M USD -1605%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 86.4M shares +47.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -48.7M USD -3389%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 401M USD +163%
Interest Paid, Excluding Capitalized Interest, Operating Activities 12K USD -7.69%
Deferred Tax Assets, Valuation Allowance 95.9M USD +50.4%
Deferred Tax Assets, Gross 96.5M USD +49.6%
Operating Lease, Liability 18.8M USD
Payments to Acquire Property, Plant, and Equipment 1.33M USD +2981%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -174M USD -73.6%
Lessee, Operating Lease, Liability, to be Paid 37.9M USD
Property, Plant and Equipment, Gross 19.4M USD +27.7%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.69M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 386K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 19.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.42M USD
Deferred Tax Assets, Operating Loss Carryforwards 34.7M USD +9.25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.82M USD +94.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.26M USD
Operating Lease, Payments 500K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 616K USD +4.76%
Deferred Tax Assets, Net of Valuation Allowance 649K USD -15.6%
Share-based Payment Arrangement, Expense 30.1M USD +80.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%